Advancing knowledge of human development, developmental disabilities, and neurodegenerative diseases.
Legend: Left panel: General patterns of [11C]PiB binding in participants with Down syndrome (DS). PiB binds to amyloid-β plaques, a neuropathological hallmark of Alzheimer’s disease (AD). The top row shows nonspecific white matter binding. The middle row shows elevated PiB binding only in the striatum (pointed out by the arrows), which is unique to the …
The link between a protein typically associated with Alzheimer’s disease and its impact on memory and cognition may not be as clear as once thought, according to a new study from the University of Wisconsin–Madison’s Waisman Center. The findings are revealing more information about the earliest stages of the neurodegenerative disease. The researchers — including …
A brain afflicted by severe Alzheimer's disease is a sad sight, a wreck of tangled neural connections and organic rubble as the lingering evidence of a fierce internal battle.
In a finding that may cause a dramatic shift in the way scientists and researchers search for a therapy for Alzheimer's disease, a team of researchers led by Jeff Johnson, an associate professor at the School of Pharmacy, has discovered that increased expression of a protein called transthyretin in the brain appears to halt the progression of the disease.
